Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ADC Therapeutics SA ADCT
$2.34
-$0.07 (-2.80%)
На 18:02, 12 мая 2023
+476.92%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
177010279.00000000
-
week52high
10.88
-
week52low
1.85
-
Revenue
209908000
-
P/E TTM
-3
-
Beta
1.10386200
-
EPS
-1.93000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 10 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 июл 2022 г. |
| RBC Capital | Outperform | Outperform | 10 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 10 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 09 сент 2022 г. |
| JP Morgan | Overweight | 21 сент 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 19 сент 2022 г. |
| RBC Capital | Outperform | Outperform | 09 ноя 2022 г. |
| B of A Securities | Neutral | Buy | 09 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 14 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 04 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
ADC Therapeutics to Participate in February Investor Conferences
Business Wire
01 февр 2023 г. в 07:15
LAUSANNE, Switzerland--( BUSINESS WIRE )--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February.
Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet
Zacks Investment Research
16 янв 2023 г. в 11:17
The mean of analysts' price targets for ADC Therapeutics SA (ADCT) points to a 174.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?
Zacks Investment Research
13 янв 2023 г. в 09:02
ADC Therapeutics SA (ADCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Land on 4 Winning Stocks Using the Overlooked Rising P/E Trick
Zacks Investment Research
06 дек 2022 г. в 08:17
Want to try an out-of-the-box approach? Tap four stocks, namely Eastside Distilling (EAST), AMC Entertainment (AMC), CuriosityStream (CURI) and ADC Therapeutics (ADCT).
ADC Therapeutics: Running Through A Stretch Of Bad Luck
Seeking Alpha
29 ноя 2022 г. в 14:30
ADCT faced the brunt of the FDA's new policy against rampant accelerated approvals. Despite positive data, Camidanlumab is not going to be in the market anytime soon.